Zobrazeno 1 - 10
of 76
pro vyhledávání: '"E Rowinsky"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. Hendifar, L. Rosen, A. McRee, A. Cercek, A. Basu-Mallick, D. Spigel, S. Tavazoie, E. Rowinsky, M. Szarek, F. Gonsalves, I. Kurth, C. Andreu, R. Busby, S. Spector, D. Darst, N. Lebaka, N. Bechar, M. Tavazoie, R. Wasserman, M. Fakih
Publikováno v:
Annals of Oncology. 33:S294
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16957bfa2522ca2d68ac27b38d88fd42
https://doi.org/10.1016/j.annonc.2022.04.215
https://doi.org/10.1016/j.annonc.2022.04.215
Autor:
E Rowinsky, Mrinal M. Patnaik, Ayalew Tefferi, Dong Chen, C A Hanson, Lasho Tl, Christopher L. Brooks, A. Pardanani, C Finke, T K Kimlinger, D Zblewski, Kaaren K. Reichard
Publikováno v:
Leukemia. 29:1605-1608
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::398b0aa0c32d39a5bebf8ed57c4ac652
https://doi.org/10.1038/leu.2015.16
https://doi.org/10.1038/leu.2015.16
Autor:
John L. Lewis, E Rowinsky, Walter B. Jones, Bonnie Reichman, Stephen C. Rubin, M. Phillips, T Hakes, Richard Barakat, John P. Curtin, Maurie Markman
Publikováno v:
Journal of Clinical Oncology. 10:1485-1491
PURPOSE To evaluate the safety and pharmacology of the intraperitoneal (IP) administration of the antineoplastic agent taxol. PATIENTS AND METHODS Twenty-five pretreated patients who were entered onto a phase I clinical trial; 24 had advanced ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19adb3b75ac5583ec2801e4f0cd602ef
https://doi.org/10.1200/jco.1992.10.9.1485
https://doi.org/10.1200/jco.1992.10.9.1485
Autor:
M, Aapro, E, Rowinsky
Publikováno v:
Anti-cancer drugs. 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::700f9638d6bc8ce415853137d7a37491
https://pubmed.ncbi.nlm.nih.gov/11340897
https://pubmed.ncbi.nlm.nih.gov/11340897
Autor:
E, Rowinsky, L, Smith, G, Rodriguez, L, White, R, Drengler, D, Von Hoff, N, Peacock, C, Aylesworth, H, Burris, P, Ravdin, R, Bellet
Publikováno v:
Oncology (Williston Park, N.Y.). 11(6 Suppl 6)
The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. Following encouraging preclinical results of taxoid combinations, this ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::354dfd5ecd85dc4fe0b9614e11d76c8b
https://pubmed.ncbi.nlm.nih.gov/9213326
https://pubmed.ncbi.nlm.nih.gov/9213326
Autor:
E. Rowinsky, Lini Pandite, P. Mudd, G. Wilding, D. Williams, S. Kathman, J. Herendeen, K. D. Holen, J. Orr, Quincy Chu
Publikováno v:
European Journal of Cancer Supplements. 2:20-21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::261afc5c33e795af827a7711eccfaba1
https://doi.org/10.1016/s1359-6349(04)80063-6
https://doi.org/10.1016/s1359-6349(04)80063-6
Autor:
A. Ricart, G. Schwartz, R. Stagg, Jamie M. Harris, G. Wilding, E. Rowinsky, A. Tolcher, G. Liu
Publikováno v:
European Journal of Cancer Supplements. 2:52-53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b65d7c95241ea74b1c068291f6adbeb
https://doi.org/10.1016/s1359-6349(04)80174-5
https://doi.org/10.1016/s1359-6349(04)80174-5
Autor:
M. Izquerido, J. Jimeno, L. Flores, M. Mita, Muralidhar Beeram, A. Patniak, Gary K. Schwartz, S.Q. Chu, E. Rowinsky, L. Lopez-Larazo
Publikováno v:
European Journal of Cancer Supplements. 2:167-168
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cffa3e21bf17de6f9bddf52bb5fb9d3
https://doi.org/10.1016/s1359-6349(04)80558-5
https://doi.org/10.1016/s1359-6349(04)80558-5
Publikováno v:
Scopus-Elsevier
PURPOSE This study was designed to define the maximum-tolerated dose (MTD) and pharmacology of paclitaxel administered by the intraperitoneal (IP) route on a weekly schedule. PATIENTS AND METHODS Thirty-three patients with residual ovarian cancer fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d337f2de4f8ef794c74f9f03c87554f
https://pubmed.ncbi.nlm.nih.gov/8523061
https://pubmed.ncbi.nlm.nih.gov/8523061